These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 10521062)

  • 41. Oral fluoropyrimidines in cancer treatment.
    Lewis NL; Meropol NJ
    Cancer Invest; 2000; 18(8):747-60. PubMed ID: 11107445
    [No Abstract]   [Full Text] [Related]  

  • 42. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
    Twelves CJ; Cassidy J
    Br J Cancer; 2002 Jun; 86(11):1670-6. PubMed ID: 12087448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
    Saif MW
    Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical development of eniluracil: current status.
    Hohneker JA
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
    Malet-Martino M; Martino R
    Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: rationale, preliminary results and perspectives.
    Corvò R; Pastrone I; Scolaro T; Marcenaro M; Berretta L; Chiara S
    Tumori; 2003; 89(4):361-7. PubMed ID: 14606636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of capecitabine dosing in colorectal cancer.
    Sun W
    Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluorouracil and the new oral fluorinated pyrimidines.
    Kuhn JG
    Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral fluoropyrimidines in colorectal cancer: a door open to the future?
    Delaunoit T; Neczyporenko F; Hendlisz A; Eisendrath P; Bleiberg H
    Acta Gastroenterol Belg; 2004; 67(4):331-3. PubMed ID: 15727077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
    Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines.
    Diasio RB
    Drugs; 1999; 58 Suppl 3():119-26. PubMed ID: 10711850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
    Yang TS; Wang JY; Tang R; Hsu KC; Chen JS
    Jpn J Clin Oncol; 2002 Sep; 32(9):352-7. PubMed ID: 12417601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.